What has emerged in neuroblastoma and other malignancies (small cell lung cancer, rhabdomyosarcoma, Wilms' tumour, retinoblastoma, acute myeloid leukaemia, and T-acute lymphoid leukaemia) is that MYCN has a great role in dysregulating the immune network. This evidence concerns the gene MYCN and retinoblastoma.